Tanezumab (RN-624) is a high-affinity, specific humanized anti-NGF monoclonal antibody (mAb) that inhibits nerve growth factor (NGF) from binding to its p75 and TrkA receptors in the peripheral nervous system. It is utilized in research investigating both acute and chronic pain conditions, including osteoarthritis, knee pain, neuralgia, and post-herpetic neuralgia [1] [2].